Home
ABOUT US
Overview
Business Model
Board of Directors
Management Team
History & Milestones
Corporate Social Responsibility
R & D PIPELINE
INVESTORS
Investor Overview
Financial Reports
Shareholders’ Meetings
Events & Presentations
NEWS
CAREERS
CONTACT
EN
中文版
NEW DRUGS FOR THE TREATMENT OF CANCER
PharmaEngine
We Race With You
DISCOVER MORE
CANCER TREATMENT PRODUCTS
ONIVYDE
A Revolutionary Durg
DISCOVER ONIVYDE
History
&
Milestones
Onivyde
Positive Topline Results from Phase III NAPOLI-3 trial of ONIVYDE® regimen (NALIRIFOX) as a first-line treatment for previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)
2022/11/9
PharmaEngine, Inc. Exercised Option for a Worldwide Exclusive License Agreement to Sentinel Oncology Limited’s CHK1 inhibitor
2022/9/25
The Results from Phase III RESILIENT trial of irinotecan liposome injection (ONIVYDE®) as a second-line monotherapy treatment for small cell lung cancer (2L SCLC)
2022/8/4
PEP07
R&D Pipeline
Events & Presentations
Organization
Our Partners
Contact Us
Go To Top